Avycaz ceftazidime/avibactam: Phase III data

Avycaz is marketed in the U.S. to treat cUTI and complicated intra-abdominal infections (cIAI). By year end, Allergan plans to submit an sNDA to FDA to include data from RECAPTURE 1 and RECAPTURE 2 in the product’s label. Avycaz is

Read the full 400 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE